

Marc Sedam serves as Vice President, Technology Opportunities and Ventures (TOV) for NYU Langone Health and New York University, joining in 2021. Marc is an expert in the commercialization of deep technology with 30 years' experience as an inventor, biotech COO, and university technology commercialization leader.

As Vice President, Marc leads the innovation and commercialization enterprise for NYU's \$1.3bn in annual research expenditures. TOV has a staff of 35 professionals covering search and evaluation, intellectual property protection, licensing, and startup creation. NYU has over 1,500 patents under management, has created >200 startup companies since the TTO was launched, and is responsible for developing Remicade—one of the most important therapies for the treatment of autoimmune disorders. He is also responsible for overseeing over \$1MM in research translation programming, including Therapeutic Alliances which is dedicated towards accelerating early-stage science into therapeutic opportunities suitable for licensing or startup creation. Marc also operates a captive \$25M venture fund on behalf of NYU Langone Health; the fund invests in startup opportunities that have the potential to positively impact human health.

Prior to NYU Langone Health, he was Vice Provost for Innovation and New Ventures and Managing Director of UNHInnovation. At UNH Marc led the creation and execution (in under 100 days) of a nationally leading COVID screening lab which processed 100,000 tests each month and was critical to continuing in-person education and on-campus operations for the university during the pandemic. His deal sheet includes hundreds of intellectual property collaborations (licenses, research collaborations, business to business transactions, global strategic partnerships, etc.), and over 75 startup companies (including two as a member of the founding team) with a total valuation over **\$5 billion dollars**.

In addition to his position with NYU, Marc is a Past Chair of AUTM, a global nonprofit leader in efforts to educate, promote and inspire professionals to support the development of academic research; was the founding director of the Peter T. Paul Entrepreneurship Center at UNH; and was the Principal Investigator of UNH's National Science Foundation I-Corps Site. Sedam also served as Chief Operating Officer of Qualyst, Inc., the scientific leader in the study of pharmaceutically relevant drug transport interactions (acquired in 2017 by BioIVT). He previously served as Associate Director of UNC-Chapel Hill's TTO and as a research scientist for National Starch and Chemical Company (now Ingredion).

Sedam holds a B.S. in biochemistry from the University of New Hampshire and an MBA from the University of North Carolina at Chapel Hill's Kenan-Flagler Business School with a focus on entrepreneurship and new ventures. Sedam is internationally recognized as an expert in the fields of innovation commercialization, early-stage startup support, regional ecosystem development, technology transfer, and innovation policy.